A Study to Learn More About the Study Medicine PF-07264660 in Healthy Chinese Adult Participants
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Other
Enrollment
12actual
Sites
2
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-24 | actual | When the study began enrolling |
| Primary completion | 2025-09-04 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-04 | actual | The whole study's end, after follow-up |
| First posted | 2024-12-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy
Interventions
- Drug: PF-07264660
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFMaximum Observed Plasma Concentration (Cmax)
measured Up to Day 181
Time to Reach Maximum Observed Plasma Concentration (Tmax)
measured Up to Day181
area under the concentration-time curve from time 0 to 336 hours (AUC336)
measured Up to Day 181
area under the concentration-time curve from time 0 to infinity (AUCinf)
measured Up to Day 181
area under the concentration-time curve from 0 to time of last measurable concentration (AUClast)
measured Up to Day 181
Terminal phase half-life (t½)
measured Up to Day 181
Incidence of treatment-emergent adverse events (TEAEs)
measured Up to Day 181
Incidence of treatment-emergent serious adverse events (SAEs)
measured Up to Day 181
Incidence of abnormal and clinically relevant changes in vital signs
measured Up to Day 181
Incidence of abnormal and clinically relevant changes in electrocardiogram
measured Up to Day 181
Incidence of abnormal and clinically relevant changes in laboratory assessments
measured Up to Day 181
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed